James Head, MD
Obstetrics & Gynecology · Alabaster, ALNPI 1740324086
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,465 of the $6,317 with a category attached, or 70.7%. 38 manufacturers reported payments, led by Medtronic at 49.2% of the total. Reporting peaked in 2019 at $3,123 and has fallen 91.5% since, to $267 in 2025. Among obstetrics & gynecology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $28.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- AbbVie$656
- Astellas Pharma US Inc$393
- Mayne Pharma Commercial LLC$201
- Hologic Sales And Service, LLC$175
- Roche Diagnostics Corporation$136
- plus $2K from 32 others
What the payments were for
- Travel & lodging$1,55625%
- Food & beverage$4,46571%
- Education$2965%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 55 | $3,111 |
| AbbVie(2 entities) | 36 | $656 |
| Astellas Pharma US Inc | 17 | $393 |
| Mayne Pharma Commercial LLC | 5 | $201 |
| Hologic Sales And Service, LLC | 13 | $175 |
| Roche Diagnostics Corporation | 6 | $136 |
| Amgen | 9 | $131 |
| Caldera Medical, Inc | 1 | $123 |
| Bayer | 7 | $118 |
| Scynexis, Inc. | 7 | $115 |
| Therapeuticsmd, Inc. | 8 | $110 |
| Sumitomo Pharma America, Inc. | 6 | $96 |
| Novo Nordisk | 5 | $87 |
| Pfizer | 4 | $85 |
| Coopersurgical, Inc. | 5 | $82 |
| Mylan Pharmaceuticals Inc. | 6 | $77 |
| Organon | 3 | $67 |
| Urovant Sciences Inc | 4 | $67 |
| Conmed Corporation | 3 | $66 |
| Axonics, Inc. | 2 | $47 |
| Boston Scientific | 2 | $43 |
| Intuitive Surgical | 1 | $39 |
| Exeltis, USA Inc. | 2 | $36 |
| Johnson & Johnson | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Meditrina | 2 | $23 |
| Davol Inc. | 1 | $21 |
| Agile Therapeutics, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Monaghan Medical Corporation | 1 | $17 |
| Minerva Surgical, Inc | 1 | $17 |
| Sage Therapeutics, LLC | 1 | $16 |
| Avion Pharmaceuticals | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Coloplast | 1 | $13 |
| Myovant Sciences Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Lupin Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,721
- INTERSTIM ICON$170
- Desara$123
How this compares
$6,317 in reported general payments places this provider in the 90th percentile of 537 obstetrics & gynecology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 67 | $41,330 |
| GemtesaVibegron | 65 | $40,200 |
| Estradiol | 284 | $8,676 |
| ValacyclovirValacyclovir Hcl | 45 | $2,597 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 98 | $2,595 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 19 | $2,482 |
| Trimethoprim | 26 | $1,519 |
| Raloxifene Hcl | 13 | $1,489 |
| Colestipol Hcl | 19 | $1,396 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 77 | $920 |
| DottiEstradiol | 17 | $912 |
| Oxybutynin Chloride ErOxybutynin Chloride | 60 | $906 |
| NitrofurantoinNitrofurantoin Macrocrystal | 21 | $886 |
| Clobetasol Propionate | 11 | $718 |
| Medroxyprogesterone Acetate | 40 | $715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $393 | $41,33067 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $96 | $40,20065 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 537 obstetrics & gynecology providers in Alabama.
Other obstetrics & gynecology in Alabaster
- Theodore TsaltasBirmingham$853K
- Richard BrownGulf Shores$429K
- Timothy HughesMobile$149K
- Allison CalhounMobile$132K
- Praful PatelDothan$65K
- Angela McCool-PearsonFairhope$57K
- Tomeka RobertsBirmingham$44K
- Percy HudsonBirmingham$29K
- Heidi StraughnBirmingham$29K
- Francois BlaudeauHomewood$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.